Search

Satyanarayana Kuchimanchi

age ~64

from Acton, MA

Satyanarayana Kuchimanchi Phones & Addresses

  • Acton, MA

Us Patents

  • Organic Compositions To Treat Hsf1-Related Diseases

    view source
  • US Patent:
    8293718, Oct 23, 2012
  • Filed:
    Dec 16, 2010
  • Appl. No.:
    12/970268
  • Inventors:
    Gregory Hinkle - Cambridge MA,
    Satyanarayana Kuchimanchi - Cambridge MA,
    Stuart Milstein - Cambridge MA,
    Markus Warmuth - Natick MA,
    Wenlai Zhou - Newton MA,
    Ping Zhu - Boxborough MA,
    Tracy S. Zimmermann - Cambridge MA,
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    C12N 15/11
  • US Classification:
    514 44A
  • Abstract:
    The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
  • Organic Compositions To Treat Hsf1-Related Diseases

    view source
  • US Patent:
    8481509, Jul 9, 2013
  • Filed:
    Feb 1, 2012
  • Appl. No.:
    13/363493
  • Inventors:
    Gregory Hinkle - Cambridge MA,
    Satyanarayana Kuchimanchi - Cambridge MA,
    Stuart Milstein - Cambridge MA,
    Markus Warmuth - Cambridge MA,
    Wenlai Zhou - Cambridge MA,
    Ping Zhu - Cambridge MA,
    Tracy S. Zimmermann - Cambridge MA,
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    C12N 15/11
  • US Classification:
    514 44A
  • Abstract:
    The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
  • Organic Compositions To Treat Hsf1-Related Diseases

    view source
  • US Patent:
    8623838, Jan 7, 2014
  • Filed:
    Feb 1, 2012
  • Appl. No.:
    13/363504
  • Inventors:
    Jinyun Chen - West Roxbury MA,
    Gregory Hinkle - Cambridge MA,
    Satyanarayana Kuchimanchi - Cambridge MA,
    Stuart Milstein - Cambridge MA,
    Markus Warmuth - Natick MA,
    Wenlai Zhou - Newton MA,
    Ping Zhu - Cambridge MA,
    Tracy S. Zimmermann - Cambridge MA,
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    C12N 15/11
    C07H 21/04
  • US Classification:
    514 44A, 536 245
  • Abstract:
    The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
  • Serpinc1 Irna Compositions And Methods Of Use Thereof

    view source
  • US Patent:
    2013031, Nov 28, 2013
  • Filed:
    Mar 15, 2013
  • Appl. No.:
    13/837129
  • Inventors:
    Alfica Sehgal - Cambridge MA,
    Ivanka Toudjarska - Cambridge MA,
    Donald Foster - Cambridge MA,
    Stuart Milstein - Cambridge MA,
    Brian Bettencourt - Cambridge MA,
    Martin A. Maier - Cambridge MA,
    Klaus Charisse - Cambridge MA,
    Satyanarayana Kuchimanchi - Cambridge MA,
  • International Classification:
    C12N 15/113
  • US Classification:
    514 44 A, 536 245, 435375, 4353201, 514 44 R
  • Abstract:
    The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
  • Organic Compositions To Treat Hsf1-Related Diseases

    view source
  • US Patent:
    2014003, Feb 6, 2014
  • Filed:
    Oct 15, 2013
  • Appl. No.:
    14/054166
  • Inventors:
    Gregory HINKLE - Cambridge MA,
    Satyanarayana KUCHIMANCHI - Cambridge MA,
    Stuart MILSTEIN - Cambridge MA,
    Markus WARMUTH - Cambridge MA,
    Wenlai ZHOU - Cambridge MA,
    Ping ZHU - Cambridge MA,
    Tracy S. ZIMMERMANN - Cambridge MA,
  • Assignee:
    NOVARTIS AG - BASEL
  • International Classification:
    C07H 21/02
    A61K 31/713
    A61K 45/06
    A61K 47/48
  • US Classification:
    514 44 A, 536 245, 530322, 530358, 536 20
  • Abstract:
    The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Get Report for Satyanarayana Kuchimanchi from Acton, MA, age ~64
Control profile